• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

GSK-backed Lyell Immunopharma, fresh off a near $500M cash injection, guns for a $150M IPO

cafead

Administrator
Staff member
  • cafead   May 26, 2021 at 11:33: AM
via Preclinical biotech Lyell Immunopharma is looking to go public after a whirlwind year of big deals and big bucks raises as it looks to use cell therapy to beat solid tumors.

article source